HBV-Targeting Oligomeric Molecules for Viral Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Hepatitis B infection are limited in effectiveness, with no specific cure available and existing therapies mainly focusing on suppressing virus replication rather than eliminating the infection, while also facing challenges in addressing the progression to liver cancer and limited treatment options for chronic infection.
Innovation Solution
Development of novel oligomeric molecules that inhibit the expression of the Hepatitis B virus genome, utilizing linker group monomers and nucleobases to target specific regions of the HBV genome, potentially integrated with lipid nanoparticles for enhanced delivery and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral antiviral agents like tenofovir or entecavir are used to treat chronic hepatitis B, then virus replication is suppressed, but the infection is not cured and treatment duration is prolonged
Solution Approach 1:
The invention uses siRNA molecules that are segmented into specific sequences targeting different regions of the HBV genome, allowing simultaneous suppression of multiple viral functions and more effective elimination of the infection
Solution Approach 2:
The patent employs chemically modified nucleotides and phosphorothioate backbones that change the physical and chemical parameters of the oligonucleotides, enhancing their stability, cellular uptake, and ability to suppress viral replication more effectively than conventional agents
2Reliability
If conventional antiviral treatments are used, then virus replication is suppressed, but progression to liver cancer is not effectively addressed
Solution Approach 1:
The siRNA molecules are designed to target multiple HBV genes simultaneously (C, P, S, and X genes), providing multi-functional activity that addresses both viral replication suppression and prevention of liver cancer development by targeting the X gene which is associated with hepatocarcinogenesis
3Quantity of substance
If existing therapies focus on suppressing virus replication, then viral load is reduced, but complete elimination of infection is not achieved
Solution Approach 1:
The invention uses siRNA molecules that are incorporated into lipid nanoparticles for targeted delivery to hepatocytes, performing preliminary action by directly delivering the therapeutic agent to the site of viral replication before the virus can complete its replication cycle and establish persistent infection
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The oligomeric molecules demonstrate significant potency in reducing HBV viral titers, serum concentrations of HBsAg and HBeAg, and HBV DNA, offering a promising therapeutic approach by simultaneously targeting all identified HBV genes, thereby potentially providing a more effective treatment for Hepatitis B infection.
Implementation Method 1
The monomers can be any nucleic acid monomers, modified nucleic acid monomers, or non-natural nucleic acid monomers... the compound has a duplex region... wherein the compound comprises a sequence of bases targeted to inhibit expression of an HBV genome
Data Source
Figure 1
Figure 2
Figure 3
AI summary
This invention encompasses compounds and compositions useful in methods for medical therapy, in general, for inhibiting Hepatitis B virus in a subject. The compounds have a first strand and a second strand, each of the strands being 19-29 monomers in length, the monomers comprising UNA monomers and nucleic acid monomers, and the compounds are targeted to a sequence of an HBV genome.